KAKarim Aljakouch

Karim Aljakouch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karim Aljakouch has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oncogenic fusions induce an extensive cancer-restricted cryptic proteome in Ewing sarcoma

    by Luuk A. Broeils, Jill Pilet, Mariia K. Koshkina, Jing Li, Sandrine Grossetete, Emma G. A. Westerink, Orson Jay, Lotta Smit, Ting Luo, Erkan Narmanli, et al.

    How tumors generate a cryptic “dark” proteome absent from healthy tissues, and whether it can be reversibly activated, remains unclear. In Ewing sarcoma, all tumors are driven by EWSR1::ETS fusions, making it a tractable model to study dark proteome activation. Integrating matched transcriptomes, translatomes and proteomes from 48 patient tumors with long-read RNA sequencing, single-cell Ribo-seq, proteomics and immunopeptidomics in cell line models, we show that EWSR1::FLI1 acts as a reversible switch recurrently inducing hundreds of cancer-specific neoproteins. Many arise from canonical coding regions via intragenic transcription start sites, generating truncated or out-of-frame neoproteins. We uncover a fusion-dependent increase in ribosomal readthrough into poly(A) tails, generating a stable 80-amino-acid TRPM4 neoprotein that, despite lacking a stop codon, is the most abundant tumor-specific microprotein across patients. Proteomic, immunopeptidomic, and immunofluorescence analyses validate neoproteins as tumor-restricted antigens, revealing a therapeutically actionable cancer dark proteome controlled by one oncogenic fusion. Highlights: Fusion proteins activate in- and out-of-frame neoproteins through intragenic transcription. Neoproteins exhibit distinct protein structures and localizations compared to their host genes. Mass spectrometry detects 911 cryptic proteins, including 29 EwS neoproteins, 15 HLA-I presented. TRPM4-dORF is a stop-less 80-aa neoprotein with abundant peptide evidence exclusively in EwS.

  • Open Access

    A single-sample workflow for joint metabolomic and proteomic analysis of clinical specimens

    by Hagen M. Gegner, Thomas Naake, Karim Aljakouch, Aurelien Dugourd, Georg Kliewer, Torsten Mueller, Dustin Schilling, Marc Andre Schneider, Nina Kunze-Rohrbach, Thomas G. P. Gruenewald, et al.

    Understanding the interplay of the proteome and the metabolome aids in understanding cellular phenotypes. To enable more robust inferences from such multi-omics analyses, combining proteomic and metabolomic datasets from the same sample provides major benefits by reducing technical variation between extracts during the pre-analytical phase, decreasing sample variation due to varying cellular content between aliquots, and limiting the required sample amount. We evaluated the advantages, practicality and feasibility of a single-sample workflow for combined proteome and metabolome analysis. In the workflow, termed MTBE-SP3, we combined a fully automated protein lysis and extraction protocol (autoSP3) with a semi-automated biphasic 75% EtOH/MTBE extraction for quantification of polar/non-polar metabolites. Additionally, we compared the resulting proteome of various biological matrices (FFPE tissue, fresh-frozen tissue, plasma, serum and cells) between autoSP3 and MTBE-SP3. Our analysis revealed that the single-sample workflow provided similar results to those obtained from autoSP3 alone, with an 85-98% overlap of proteins detected across the different biological matrices. Additionally, it provides distinct advantages by decreasing (tissue) heterogeneity by retrieving metabolomics and proteomic data from the identical biological material, and limiting the total amount of required material. Lastly, we applied MTBE-SP3 to a lung adenocarcinoma cohort of 10 patients. Integrating the metabolic and proteomic alterations between tumour and non-tumour adjacent tissue yielded consistent data independent of the method used. This revealed mitochondrial dysfunction in tumor tissue through deregulation of OGDH, SDH family enzymes and PKM. In summary, MTBE-SP3 enables the facile and confident parallel measurement of proteins and metabolites obtained from the same sample. This workflow is particularly applicable for studies with limited sample availability and offers the potential to enhance the integration of metabolomic and proteomic datasets.


  • Open Access

    Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level

    by Mohamad K. Hammoud, Hesham K. Yosef, Tatjana Lechtonen, Karim Aljakouch, Martin Schuler, Wissam Alsaidi, Ibrahim Daho, Abdelouahid Maghnouj, Stephan Hahn, Samir F. El-Mashtoly, et al.

    Monitoring the drug efficacy or resistance in vitro is usually carried out by measuring the response of single few proteins. However, observation of single proteins instead of an integral cell response may lead to results that are not consistent with patient’s response to a drug. We present a Raman spectroscopic method that detects the integral cell response to drugs such as tyrosine kinase inhibitors (TKIs). Non-small cell lung cancer (NSCLC) patients with EGFR mutations develop acquired resistance to first (erlotinib)- and third (osimertinib)-generation TKIs. Large erlotinib-induced differences were detected by Raman micro-spectroscopy in NSCLC cells without T790M EGFR mutation but not in cells with this mutation. Additionally, Raman difference spectra detected the response of NSCLC cells with T790M EGFR mutation to second- (neratinib) and third-generation (osimertinib) TKIs, and the resistance of cells with T790M/C797S EGFR mutation to osimertinib. Thus, the in vitro Raman results indicated that NSCLC cells with T790M and T790M/C797S EGFR mutations are resistant to erlotinib- and osimertinib, respectively, consistent with the observed responses of patients. This study shows the potential of Raman micro-spectroscopy to monitor drug resistance and opens a new door to in vitro companion diagnostics for screening personalized therapies.


  • Open Access

    Raman‐mikrospektroskopischer Nachweis für den Metabolismus eines Tyrosinkinase‐Inhibitors, Neratinib, in Krebszellen

    by Karim Aljakouch, Tatjana Lechtonen, Hesham K. Yosef, Mohamad K. Hammoud, Wissam Alsaidi, Carsten Kötting, Carolin Mügge, Robert Kourist, Samir F. El‐Mashtoly, Klaus Gerwert

    Tyrosinkinase‐Rezeptoren sind eines der Hauptziele in der Krebstherapie. Sie spielen eine wesentliche Rolle bei der Modulation der Wachstumsfaktor‐Signalwege und induzieren dadurch Zellproliferation und ‐wachstum. Tyrosinkinase‐Inhibitoren wie Neratinib binden an EGFR‐ und HER2‐Rezeptoren und zeigen Antitumoraktivität. Es ist jedoch wenig über ihre genaue zelluläre Aufnahme und den Stoffwechsel bekannt. Hier berichten wir zum ersten Mal über die intrazelluläre räumliche Verteilung und den Metabolismus von Neratinib in verschiedenen Krebszellen durch markerfreies Raman‐Imaging. Zwei neue Neratinib‐Metaboliten wurden nachgewiesen, und das Fluoreszenz‐Imaging derselben Zellen zeigt, dass sich Neratinib in Lysosomen akkumuliert. Die Ergebnisse deuten auch darauf hin, dass sowohl EGFR als auch HER2 dem klassischen endosomalen/lysosomalen Stoffwechselweg zum Abbau folgen. Eine Kombination aus Raman‐Mikroskopie, DFT‐Rechnungen und LC‐MS wurde verwendet, um die chemische Struktur von Neratinib‐Metaboliten zu identifizieren. Diese Ergebnisse zeigen das Potenzial der Raman‐Mikroskopie zur Untersuchung der Arzneimittel‐Pharmakokinetik.


  • Open Access

    Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells

    by Karim Aljakouch, Tatjana Lechtonen, Hesham K. Yosef, Mohamad K. Hammoud, Wissam Alsaidi, Carsten Kötting, Carolin Mügge, Robert Kourist, Samir F. El‐Mashtoly, Klaus Gerwert

    Tyrosine kinase receptors are one of the main targets in cancer therapy. They play an essential role in the modulation of growth factor signaling and thereby inducing cell proliferation and growth. Tyrosine kinase inhibitors such as neratinib bind to EGFR and HER2 receptors and exhibit antitumor activity. However, little is known about their detailed cellular uptake and metabolism. Here, we report for the first time the intracellular spatial distribution and metabolism of neratinib in different cancer cells using label‐free Raman imaging. Two new neratinib metabolites were detected and fluorescence imaging of the same cells indicate that neratinib accumulates in lysosomes. The results also suggest that both EGFR and HER2 follow the classical endosome lysosomal pathway for degradation. A combination of Raman microscopy, DFT calculations, and LC‐MS was used to identify the chemical structure of neratinib metabolites. These results show the potential of Raman microscopy to study drug pharmacokinetics.